Halozyme Therapeutics (NASDAQ:HALO) Given “Buy” Rating at HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports.

A number of other equities analysts have also issued reports on HALO. Benchmark reaffirmed a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Stock Up 2.4 %

HALO stock opened at $59.53 on Thursday. The stock has a market capitalization of $7.33 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. The company has a 50-day moving average of $55.20 and a two-hundred day moving average of $54.74. Halozyme Therapeutics has a 52-week low of $37.73 and a 52-week high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, equities research analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of HALO. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $69,000. RPg Family Wealth Advisory LLC bought a new position in shares of Halozyme Therapeutics in the third quarter worth about $1,886,000. Segall Bryant & Hamill LLC lifted its position in shares of Halozyme Therapeutics by 16.3% during the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after purchasing an additional 49,856 shares in the last quarter. Retirement Systems of Alabama grew its stake in shares of Halozyme Therapeutics by 23.5% during the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after purchasing an additional 74,173 shares during the last quarter. Finally, South Street Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at approximately $9,812,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.